In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Sanofi-aventis and Regeneron Pharmaceuticals reaffirm development commitment
Regeneron And Aventis Begin Study Of Intravenous VEGF Trap In Cancer
Aventis and Regeneron enter global partnership to develop and commercialize the VEGF Trap
Bayer HealthCare and Regeneron to collaborate on VEGF Trap for the treatment of eye diseases
Regeneron Announces VelociGene(R) Agreement with Sanofi-Aventis
TRANSFER OF COMMERCIAL RIGHTS OF PLAVX® IN JAPAN TO SANOFI-AVENTIS
Sanofi-aventis to collaborate with Combinature on combinatorial biosynthesis
Termination of marketing alliance on Rulid tablets 150mg
Bayer and Regeneron extend development program for VEGF Trap-Eye